Consolidated Net Sales: Approximately $1.4 billion, consistent with prior year. Adjusted EBITDA: $166 million, down from $191 million in the prior year. Net Loss: $4 million or $0.03 per diluted share, compared to net income of $54 million or $0.36 per diluted share in the prior year. TSS Net Sales: $466 million, a 3% increase from the prior year. TSS Adjusted EBITDA Margin: 30%, decreased by 3 percentage points. TT Net Sales: $597 million, a 1% increase year-over-year. TT Adjusted EBITDA: $50 million, a 28% decrease compared to the prior year. APM Net Sales: $294 million, a 3% decrease compared to the prior year. APM Adjusted EBITDA Margin: Increased by 1 percentage point to 11%. Capital Expenditures: $84 million, an 18% decrease compared to the prior year. Free Cash Flow: Use of $196 million, compared to a use of $392 million in the prior year. Gross Debt: $4.1 billion with approximately $1.1 billion in total liquidity. Dividend Reduction: Declared a dividend for the second quarter at a reduced rate of $8.75 per share, reflecting a 65% reduction. Warning! GuruFocus has detected 8 Warning Signs with CC. Release Date: May 07, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points The Chemours Co (NYSE:CC) reported a 40% year-over-year net sales increase in Opteon Refrigerants, driven by increased demand for blend due to the US AIM Act transition mandate. The company successfully ramped up its 40% capacity expansion of Opteon feedstock at the Corpus Christi site, ensuring no disruption to customer orders despite a brief outage. Chemours' TSS business achieved a 30% adjusted EBITDA margin, positioning well for the peak cooling season. The company has a strategic agreement with Navin Fluorine to produce Opteon two-phase immersion cooling fluid, addressing data cooling center needs. Chemours anticipates a significant cash flow benefit of approximately $100 million to $115 million from the expiration of high-grade ore feedstock contracts by 2027. Negative Points Chemours reported a net loss of $4 million for the first quarter, compared to a net income of $54 million in the prior year. The company's adjusted EBITDA decreased to $166 million from $191 million in the prior year, primarily due to lower pricing and unfavorable currency movements. Chemours' TT segment faced challenges with lower pricing and additional costs from plant downtime due to cold weather. The APM segment experienced a 3% decrease in net sales due to weakened cyclical end markets and products serving the hydrogen market. Chemours reduced its dividend by 65% to $8.75 per share to balance capital return to shareholders with balance sheet flexibility. Story Continues Q & A Highlights Q: Can you provide details on the strategic venture with Navin Fluorine and its capacity? A: Denise Dignam, President and CEO, explained that the partnership with Navin Fluorine is crucial for commercialization. They are investing $14 million in the asset, which is sized for both commercial lease stages and process technology refinement. This will support field trials, with the capacity to conduct dozens of trials and expand volume as customer commitments are secured. Q: Regarding TiO2, is 2025 EBITDA expected to be higher than 2024, and can you clarify the ore savings? A: Shane Hostetter, CFO, confirmed that 2025 EBITDA for TiO2 is expected to be better than 2024. The ore savings, ranging from $100 million to $150 million, are cash flow benefits expected as contracts expire in 2026 and 2027, with significant benefits anticipated in 2027. Q: Why was the dividend cut now, and why not eliminate it completely? A: Shane Hostetter, CFO, stated that resizing the dividend provides balance sheet flexibility to execute strategic priorities and grow the company. The reduction aligns with an appropriate payout in the chemicals and industrial space, maintaining attractiveness while allowing financial flexibility. Q: How are TiO2 prices trending in regulated markets, and what is the outlook? A: Denise Dignam, President and CEO, noted price stabilization in fair-trade markets with volume increases. They do not provide forward pricing guidance but see stabilization in these markets. Q: What are the assumptions for the cash flow conversion range in the second half of the year? A: Shane Hostetter, CFO, explained that the range is influenced by working capital unwind and earnings dynamics. The lower investments in the second half are due to a focus on critical and essential spending, with capital expenditures adjusted to reflect this strategy. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
The Chemours Co (CC) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...